About MITRO

Company Profile

Management Team

Evolution

News

MITRO Acquires Xing Imaging LLC to Strengthen Clinical Accompanying Diagnosis and Nuclear Drug Imaging Service Capabilities!

2022-12-12 14:44

 
On December 10, 2022,MITRO (Nanjing) Biotech Co., Ltd. announced the acquisition of Xing Imaging LLC, located in Delaware, USA, focusing on nuclear drug conversion and clinical trial imaging CRO service company, using the preparation quality control technology of new PET drugs, PET scanning services of new PET drugs and image reading management experience to assist international pharmaceutical companies in accurate imaging diagnosis CRO services during clinical trials.
 
The acquisition will further strengthen the ability of MITRO in clinical accompanying diagnosis and nuclear drug imaging services, create a new nuclear drug clinical transformation network, and improve the company's industrial layout in the field of nuclear medicine CRO.
 
Under the terms of the acquisition agreement, MITRO will acquire Xing Imaging LLC for $30.2 million, which includes advance payment, project node payment and performance gambling award.
                                                       
 
Wu Haowei, CEO of MITRO said, "Xing Imaging LLC is unique in that its strong network of PET centers can provide industry partners with state-of-the-art neuro-PET imaging tracers, I am pleased that this acquisition provides a full range of molecular imaging clinical study services previously unavailable in China. It is a perfect combination of two companies, and we will work together to accelerate the development of new drugs, from nuclear medicine drug R & D to all stages of clinical study in China."
 
Wu Haowei said, "Our two teams have been working together for many years, and our relationship and the services we provide will be strengthened and enriched by the combination of each team's different experiences and capabilities. We believe that our combination will address the rapidly growing demand for PET molecular imaging services in clinical trials."
 
Dr. Gilles Tamagnan, Co-Founder and CEO of Xing Imaging LLC said, "This is a huge opportunity to further our commitment to Chinese patients by providing clinical molecular imaging services as an important part of our research to evaluate new therapeutic drugs. This joint represents the beginning of a larger strategy to expand these services in China and other regions."
 
 
 
XING Imaging 
 
Xing Imaging LLC is a clinical PET imaging services company registered in the United States and operating in China. At present, the main business scope includes,Specializing in radiotracer production, PET acquisition and analysis; taking advantage of unique opportunities to meet the needs of PET clinical imaging research in China; as a biomarker imaging company, it provides end-to-end service support for radiopharmaceutical imaging. The co-founders and company management of Xing Imaging LLC have an average of more than 25 years of experience.
 
MITRO
For radiopharmaceuticals, MITRO provides a one-stop service from early development, pharmaceutical studies, pre-clinical studies, clinical studies and registration. MITRO has experience in radiopharmaceutical development and declaration,It has already helped 4 18F-Drugs and 1 99mTc-Drug get clinical approvals, there are more than 10 radiopharmaceuticals in the process of implementation (18F,  68Ga, 89Zr, 90Y, 99mTc, 166Ho, 177Lu).
About Us
MITRO (Nanjing) Biotech Co., Ltd. was established in 2012. As a domestic molecular imaging pharmaceutical R & D outsourcing (MI-CRO) enterprise, its molecular imaging core technology has outstanding advantages such as in vivo imaging, dynamic quantification, self-control, continuous observation, etc., which can help pharmaceutical companies greatly shorten the drug R & D cycle, reduce the risk of failure and speed up the listing of new drugs. With the technology of radiolabeling (Radiolabeling) and molecular imaging (Molecular Imaging), Mitro Biotech can provide customers at home and abroad with the overall solution of new drug research and development, such as drug screening, biodistribution, pharmacokinetic study, pharmacodynamic evaluation and so on, and outsourced technical services. Its business includes the transformation research from nude (mouse), rat, monkey to human body, focus on tumor, cardiovascular and cerebrovascular, Alzheimer's disease, Parkinson's disease, epilepsy, rheumatic immunity, diabetes, NASH and other major diseases, as well as receptor, gene, stem cell and other cutting-edge research fields, explore the mechanism of disease, develop diagnosis and treatment drugs, and evaluate the treatment effect. At the same time, MITRO provides a one-stop service for radiopharmaceuticals from early development, CMC, preclinical, clinical and registration.